Treatment of Menstrual Migraines

Acute Treatment Strategy

The American Academy of Neurology recommends NSAIDs as the initial acute treatment choice, with the strongest evidence supporting acetylsalicylic acid, ibuprofen, and diclofenac potassium 1
Naproxen or naproxen sodium shows modest but statistically significant effects on headache frequency 2
Triptans should be offered when NSAIDs provide inadequate relief, and must be taken early in the attack when headache is still mild 1

The American College of Obstetricians and Gynecologists suggests that hormonal approaches, such as transcutaneous estradiol 1.5 mg, have grade B evidence of efficacy for perimenstrual prophylaxis, but evidence does not support benefit in patients whose migraines are not menstruation-related 2

The American Academy of Neurology recommends paracetamol as first-line medication during pregnancy, despite relatively poor efficacy, and NSAIDs can only be used during the second trimester 3
For breastfeeding women, paracetamol is preferred, though ibuprofen and sumatriptan are considered safe 3

The American Family Physician suggests that magnesium has shown benefits over placebo in two studies for prevention 2
High-dose vitamin B2 (riboflavin 400 mg) showed significant benefit at three and four months after initiation 2

Approximately 50% of women with migraine experience increased attacks during their menstrual period, though only about 8% have attacks exclusively related to menstruation, according to the American Academy of Neurology 4
Menstrually-related migraine affects approximately 6-7% of women, while pure menstrual migraine affects only about 1-8% of women, as reported by the American Headache Society 4

Any woman of reproductive age presenting with migraine should be asked about the relationship between her attacks and menstruation, as recommended by the American College of Obstetricians and Gynecologists 4
If optimized acute medication therapy does not suffice for women with confirmed menstrual migraine, perimenstrual preventive treatment should be initiated with a long-acting NSAID or triptan for 5 days, beginning 2 days before the expected first day of menstruation, according to the American Academy of Neurology 4 and the European Headache Federation 5

In reproductive‑age women with menstrual migraine who require continuous prophylaxis, the American College of Physicians recommends initiating treatment with first‑line agents such as β‑blockers (metoprolol or propranolol), valproate, venlafaxine, or amitriptyline. 6
If first‑line agents are ineffective or not tolerated, the guideline advises progressing to second‑line therapies—specifically CGRP‑targeted oral gepants or CGRP monoclonal antibodies—for ongoing migraine prevention. 6
Topiramate is reserved as a third‑line option and should be introduced only after adequate trials of both first‑line medications and CGRP‑targeted therapies have failed. 6

Patients should be counseled that preventive medication benefits typically emerge gradually over several weeks rather than providing immediate relief, emphasizing realistic adherence expectations. 6
Cost analysis within the guideline highlights that CGRP‑targeted treatments are considerably more expensive than traditional oral preventives, and patients generally prefer oral formulations over injectable options. 6